VF
PLRX icon

Virtu Financial’s Pliant Therapeutics PLRX Stock Holding History

Virtu Financial’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-48,037
Closed -$870K – 1755
2023
Q2 		$870K Buy
48,037
+38,887
+425% +$921K 0.07% 240
2023
Q1 		$243K Buy
+9,150
New +$261K 0.03% 643

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Virtu Financial's PLRX Position: Q3 2023 in Review

Virtu Financial sold out of Pliant Therapeutics (PLRX) in Q3 2023, closing a stake of 48,037 shares — an estimated $870K sold.

Virtu Financial first reported a position in PLRX in Q1 2023 and held it in 2 quarters. The position peaked at $870K in Q2 2023. 136 funds tracked by Wall St. Rank hold PLRX as of Q3 2023.

  • Virtu Financial reported no remaining Pliant Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Virtu Financial sold 48,037 Pliant Therapeutics shares in Q3 2023, an estimated $870K.
  • Virtu Financial first reported a position in Pliant Therapeutics in Q1 2023 and held it in 2 quarters.
  • Virtu Financial's Pliant Therapeutics position peaked at $870K in Q2 2023.
  • 136 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2023.

Based on Virtu Financial's 13F filing for Q3 2023, filed 15 Nov 2023.